Featured Publications
Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American childrenInvasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
Yildirim I, Lapidot R, Shaik-Dasthagirisaheb Y, Hinderstein S, Lee H, Klevens M, Grant L, Arguedas Mohs A, Cane A, Madoff L, Johnson H, Ivanof C, Burns M, Pelton S. Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use. Pediatrics 2023, 153 PMID: 38087952, DOI: 10.1542/peds.2023-063039.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseIPD casesPCV13 eraPneumococcal diseaseCases of IPDIncidence of IPDRates of IPDPneumococcal conjugate vaccine useSerotype 15B/CImplementation of PCV13Non-PCV13 serotypesPneumococcal conjugate vaccineConfidence intervalsStatewide surveillance systemIPD incidence ratesIPD ratesPenicillin nonsusceptibilityConjugate vaccineVaccine serotypesSerotype 19ASterile sitesIncidence rateVaccine useLower incidenceVaccine formulationsRelationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study
Patel KM, Shafiq M, Malik AA, Cobanoglu A, Klotz M, Eric Humphries J, Lee A, Murray T, Wilkinson D, Yildirim I, Elharake JA, Diaz R, Rojas R, Kuperwajs Cohen A, Omer SB, Gilliam WS. Relationship between the use of nonpharmaceutical interventions and COVID-19 vaccination among U.S. child care providers: A prospective cohort study. Vaccine 2022, 40: 4098-4104. PMID: 35660329, PMCID: PMC9135692, DOI: 10.1016/j.vaccine.2022.05.064.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationProspective cohort studyCare providersNonpharmaceutical interventionsChild care providersCohort studyLikelihood of vaccinationPreventative health behaviorsVaccinationHealth behaviorsCare programMandatory vaccinationSignificant associationVaccine mandatesDistrict of ColumbiaLarge healthInterventionPandemic controlCOVID-19Child care programsProvidersEmail surveyNonadherenceMeasuresPrevalence of Chronic Diseases, Depression, and Stress Among US Childcare Professionals During the COVID-19 Pandemic
Elharake JA, Shafiq M, Cobanoglu A, Malik AA, Klotz M, Humphries JE, Murray T, Patel KM, Wilkinson D, Yildirim I, Diaz R, Rojas R, Cohen A, Lee A, Omer SB, Gilliam WS. Prevalence of Chronic Diseases, Depression, and Stress Among US Childcare Professionals During the COVID-19 Pandemic. Preventing Chronic Disease 2022, 19: e61. PMID: 36137183, PMCID: PMC9541678, DOI: 10.5888/pcd19.220132.Peer-Reviewed Original ResearchConceptsPhysical health conditionsMental healthHealth conditionsChronic diseasesDepression ratesCOVID-19 pandemicSex/gender disparityPublic health officialsChildcare professionalsSevere asthmaHeart diseaseUS adultsAsthma ratesSociodemographic characteristicsHealth officialsDepressionDiseaseNational representativenessLinear regression modelsPrevalenceHealthRegression modelsPandemicProfessionalsGender disparities
2024
BK polyomavirus DNAemia, allograft rejection, and de novo donor‐specific antibodies after lowering target tacrolimus levels in pediatric kidney transplant recipients
Huang H, Xiang Y, George R, Winterberg P, Serluco A, Liverman R, Yildirim I, Garro R. BK polyomavirus DNAemia, allograft rejection, and de novo donor‐specific antibodies after lowering target tacrolimus levels in pediatric kidney transplant recipients. Pediatric Transplantation 2024, 28: e14791. PMID: 38808701, DOI: 10.1111/petr.14791.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibodiesTarget tacrolimus levelsDevelopment of de novo donor-specific antibodiesBiopsy-proven rejectionDonor-specific antibodiesMonths post-KTTacrolimus levelsTime of transplantationPediatric KT recipientsBK polyomavirusBKV-DNAemiaPost-KTPost-intervention cohortAllograft rejectionRecipient ageKT recipientsKidney transplantationPediatric kidney transplant recipientsLow tacrolimus levelsReduction of immunosuppressionKaplan-Meier survival analysisYounger recipient ageIndividualized immunosuppressive regimensKidney transplant recipientsRetrospective chart reviewDevelopment and comparison of immunologic assays to detect primary RSV infections in infants
Anderson L, Jadhao S, Hussaini L, Ha B, McCracken C, Gibson T, Yildirim I, Yi J, Stephens K, Korski C, Kao C, Sun H, Lee C, Jaunarajs A, Rostad C, Anderson E. Development and comparison of immunologic assays to detect primary RSV infections in infants. Frontiers In Immunology 2024, 14: 1332772. PMID: 38283339, PMCID: PMC10811012, DOI: 10.3389/fimmu.2023.1332772.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusIgG enzyme immunoassayNeutralizing antibody assaysELISPOT assayAntibody assayRSV antibodiesEnzyme immunoassayRSV infectionSubgroup ARespiratory syncytial virus seasonDocumented RSV infectionPrimary RSV infectionEffective respiratory syncytial virusVaccine clinical trialsEvidence of past infectionEpidemiological studiesRed cell lysisYoung childrenMaternal microchimerismPBMC specimensPregnant womenIFN-gSyncytial virusAntibody enzyme immunoassayELISPOT
2023
Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis
Liverman R, Serluco A, Nance G, George R, Rodriguez D, Deshpande S, Mao C, Garro R, Yildirim I. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation 2023, 27: e14493. PMID: 36945819, DOI: 10.1111/petr.14493.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsPediatric solid organ transplant recipientsCytomegalovirus DNAemiaValganciclovir prophylaxisDose reductionRisk factorsTransplant recipientsImpact of dose adjustmentsRisk factors associated with failureFactors associated with failureOrgan transplant recipientsHeart transplant recipientsIndependent risk factorRetrospective cohort studyAssociated with morbidityCMV DNAemiaCytomegalovirus eventsValganciclovir dosingImmunosuppressive therapyDose adjustmentYounger age groupsDNAemiaValganciclovirRisk stratificationAdverse events
2022
Vaccination in pediatric solid organ transplant: A primer for the immunizing clinician
Chen JK, Cheng J, Liverman R, Serluco A, Corbo H, Yildirim I. Vaccination in pediatric solid organ transplant: A primer for the immunizing clinician. Clinical Transplantation 2022, 36: e14577. PMID: 34997642, DOI: 10.1111/ctr.14577.Peer-Reviewed Original ResearchConceptsVaccine-preventable illnessesPediatric solid organ transplant recipientsSolid organ transplant recipientsPediatric solid organ transplantCorrect immunization schedulesPrevention's Advisory CommitteeOrgan transplant recipientsSolid organ transplantsInfectious Diseases SocietyTime of transplantTransplant recipientsDiseases SocietyVaccine recommendationsIncomplete immunizationImmunization scheduleAntibody titersInadequate responseOrgan transplantsElevated riskPreventable illnessMultiple guidelinesVaccine managementRapid catchDisease controlAmerican SocietyAssociation of Child Masking With COVID-19–Related Closures in US Childcare Programs
Murray TS, Malik AA, Shafiq M, Lee A, Harris C, Klotz M, Humphries JE, Patel KM, Wilkinson D, Yildirim I, Elharake JA, Diaz R, Reyes C, Omer SB, Gilliam WS. Association of Child Masking With COVID-19–Related Closures in US Childcare Programs. JAMA Network Open 2022, 5: e2141227. PMID: 35084484, PMCID: PMC8796014, DOI: 10.1001/jamanetworkopen.2021.41227.Peer-Reviewed Original ResearchConceptsCOVID-19 casesLower riskImportant public health policy implicationsCOVID-19-related closuresPublic health policy implicationsChildren 2 yearsElectronic survey studyCenter-based childcare programsHealth policy implicationsSARS-CoV-2Survey studyChildcare professionalsMAIN OUTCOMEProgram closureHealth policyStudy periodRobust SEsBaselineChildcare programsCOVID-19Young childrenChildcare settingsChildrenPhysical distancingAssociation
2021
Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.
Yee ME, Lai KW, Bakshi N, Grossman JK, Jaggi P, Mallis A, Wang YF, Jerris RC, Lane PA, Yildirim I. Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019. Pediatrics 2021, 149 PMID: 34913059, PMCID: PMC8959248, DOI: 10.1542/peds.2021-051892.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBloodstream infectionsBlood culturesSickle cell anemia genotypesRetrospective cohort studyInvasive bacterial infectionsMultivariate logistic regressionConfidence intervalsAverage incidence rateSpectrum of pathogensAntibiotic prophylaxisEligible patientsFunctional aspleniaBSI episodesCohort studyChronic transfusionMedian ageAnnual incidenceOverall incidenceRisk factorsIncidence rateCell diseaseEmpirical treatmentBordetella holmesiiCommon pathogensCOVID-19 Vaccine Uptake Among US Child Care Providers
Patel KM, Malik AA, Lee A, Klotz M, Humphries JE, Murray T, Wilkinson D, Shafiq M, Yildirim I, Elharake JA, Diaz R, Reyes C, Omer SB, Gilliam WS. COVID-19 Vaccine Uptake Among US Child Care Providers. Pediatrics 2021, 148: e2021053813. PMID: 34452977, PMCID: PMC9277775, DOI: 10.1542/peds.2021-053813.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine uptakeVaccine uptakeCare providersChild care providersVaccination ratesSevere acute respiratory syndrome coronavirus 2Adult populationState public health leadersUS general adult populationAcute respiratory syndrome coronavirus 2General US adult populationRespiratory syndrome coronavirus 2Home-based child care programsSyndrome coronavirus 2US adult populationGeneral adult populationCross-sectional surveyPublic health implicationsPublic health leadersAnnual household incomeCoronavirus 2Care settingsInclusion criteriaCare programChild care settingsA Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children
Yildirim I, Kao CM, Tippett A, Suntarattiwong P, Munye M, Yi J, Elmontser M, Quincer E, Focht C, Watson N, Bilen H, Baker JM, Lopman B, Hogenesch E, Rostad CA, Anderson EJ. A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children. Clinical Infectious Diseases 2021, 73: 1759-1767. PMID: 34410341, PMCID: PMC8599178, DOI: 10.1093/cid/ciab709.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessInfluenza-positive casesInfluenza-related hospitalizationsVaccine effectivenessInfluenza seasonOdds ratioInfluenza ALaboratory-confirmed influenza-related hospitalizationsTest-negative case-control study designAdjusted vaccine effectivenessInfluenza-negative controlsTest-negative controlsCase-control study designHospitalization of childrenTest-negative casesConfidence intervalsNon-Hispanic blacksLogistic regression modelsPreventing HospitalizationInfluenza vaccinationInfluenza burdenMedian ageInfluenza B.Influenza infectionPediatric hospitalizationsSafety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Arrieta AC, Neely M, Day JC, Rheingold SR, Sue PK, Muller WJ, Danziger-Isakov LA, Chu J, Yildirim I, McComsey GA, Frangoul HA, Chen TK, Statler VA, Steinbach WJ, Yin DE, Hamed K, Jones ME, Lademacher C, Desai A, Micklus K, Phillips DL, Kovanda LL, Walsh TJ. Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00290-21. PMID: 34031051, PMCID: PMC8284446, DOI: 10.1128/aac.00290-21.Peer-Reviewed Original ResearchConceptsPhase 1 studyPediatric patientsIsavuconazonium sulfatePlasma drug exposureDrug exposureOral administrationImmunocompromised Pediatric PatientsNew triazole agentProdrug isavuconazonium sulfateTolerability of isavuconazoleBody mass indexPopulation PK modelInvasive fungal infectionsProbability of targetTarget rangeConcentration-time curveFirst-order inputMass indexPopulation pharmacokineticsStepwise covariate modelingTriazole agentsClinical dosePK parametersLinear eliminationPatientsClinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections
Yi J, Wood JB, Creech CB, Williams D, Jimenez-Truque N, Yildirim I, Sederdahl B, Daugherty M, Hussaini L, Munye M, Tomashek KM, Focht C, Watson N, Anderson EJ, Thomsen I. Clinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections. The Journal Of Pediatrics 2021, 234: 236-244.e2. PMID: 33771580, PMCID: PMC8238832, DOI: 10.1016/j.jpeds.2021.03.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAnti-Bacterial AgentsArthritis, InfectiousChildChild, PreschoolCombined Modality TherapyFemaleGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHumansInfantLogistic ModelsMaleMethicillin-Resistant Staphylococcus aureusOrthopedic ProceduresOsteomyelitisRetrospective StudiesStaphylococcal InfectionsTreatment OutcomeUnited StatesConceptsOsteomyelitis/septic arthritisAcute hematogenous osteomyelitisMethicillin-resistant S aureusSeptic arthritisHematogenous osteomyelitisTreatment failureS aureusOral therapyAntibiotic therapyMusculoskeletal infectionsHigher oddsPediatric musculoskeletal infectionsLonger hospital stayOral antibiotic therapyRetrospective cohort studyTreatment-related complicationsTreatment-associated complicationsHospital stayPediatric infectionsCohort studyParenteral therapyTreatment complicationsIntensive careRecurrent infectionsWorse outcomes
2020
Vaccine‐induced protection against hepatitis B in pediatric solid organ transplant patients
Ball M, Liverman R, Serluco A, Yildirim I. Vaccine‐induced protection against hepatitis B in pediatric solid organ transplant patients. Pediatric Transplantation 2020, 25: e13920. PMID: 33217081, DOI: 10.1111/petr.13920.Peer-Reviewed Original ResearchConceptsVaccine-induced protectionPediatric solid organ transplant patientsSolid organ transplant patientsOrgan transplant patientsHepatitis B virusHBV vaccinationTransplant patientsHepatitis B surface antibody titerHBV vaccination coverageHBV vaccine seriesPediatric SOT recipientsDetailed chart reviewYears of ageHBsAb titersSeroprotection ratesSOT recipientsHBV infectionTransplanted childrenVaccine seriesChart reviewHepatitis BLaboratory featuresImmunogenicity dataVaccination coverageVaccine immunityRecognition and Outcomes of Pneumococcal Meningitis in 2 Tertiary Pediatric Hospitals Since the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine
Stevens JP, Lively A, Jerris R, Yildirim I, Lantis P. Recognition and Outcomes of Pneumococcal Meningitis in 2 Tertiary Pediatric Hospitals Since the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine. Pediatric Emergency Care 2020, 38: e354-e359. PMID: 33181795, DOI: 10.1097/pec.0000000000002288.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccineLumbar puncturePneumococcal meningitisConjugate vaccineMeningeal signsLow suspicionMental statusPositive cerebrospinal fluid culturesLonger hospital lengthStreptococcus pneumoniae meningitisCerebrospinal fluid culturesCranial nerve palsyHours of admissionTertiary pediatric hospitalPoor clinical outcomeTertiary healthcare systemPneumococcal meningitis casesPneumococcal immunizationPneumoniae meningitisHospital lengthNerve palsyPrimary outcomeAntibiotic administrationClinical outcomesPediatric hospitalThe burden of respiratory syncytial virus infections among children with sickle cell disease
Rostad CA, Maillis AN, Lai K, Bakshi N, Jerris RC, Lane PA, Yee ME, Yildirim I. The burden of respiratory syncytial virus infections among children with sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28759. PMID: 33034160, PMCID: PMC8246443, DOI: 10.1002/pbc.28759.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSickle cell diseaseRespiratory viral panelRSV-positive casesRSV infectionAnnual incidenceHospitalization ratesCell diseaseBurden of RSVPediatric lower respiratory tract infectionsLaboratory-confirmed RSV infectionRespiratory syncytial virus infectionRSV-related hospitalization rateLower respiratory tract infectionsRSV positive testRSV-negative childrenRSV-negative patientsAcute chest syndromeSyncytial virus infectionRespiratory tract infectionsAverage annual incidenceMultivariate logistic regressionConfidence intervalsCase-control studyOutcome of childrenMicrobiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease
Kao CM, Yee ME, Maillis A, Lai K, Bakshi N, Rostad BS, Jerris RC, Lane PA, Yildirim I. Microbiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease. Pediatric Blood & Cancer 2020, 67: e28517. PMID: 32710705, PMCID: PMC8369475, DOI: 10.1002/pbc.28517.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMethicillin-susceptible Staphylococcus aureusMagnetic resonance imagingAntibiotic treatmentOperative culturesCell diseaseLarge tertiary pediatric centerPrescribed antibiotic treatmentTertiary pediatric centerCulture-positive casesKey presenting symptomsChildren ages 6Bone painMicrobiologic etiologyPresenting symptomPediatric centersBone infarctsMedical chartsMicrobiologic findingsRadiographic featuresImaging featuresOsteomyelitisProbable osteomyelitisDiagnostic codingTissue debridementInitial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosingSevere Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia
Patel PA, Chandrakasan S, Mickells GE, Yildirim I, Kao CM, Bennett CM. Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia. Pediatrics 2020, 146: e20201437. PMID: 32366611, PMCID: PMC7329259, DOI: 10.1542/peds.2020-1437.Peer-Reviewed Original ResearchConceptsSevere acute respiratory distress syndromeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Coronavirus disease 2019Respiratory failureSevere thrombocytopeniaCoronavirus 2Disease 2019Pediatric coronavirus disease 2019Airway pressure release ventilationAcute respiratory distress syndromeBroad antiviral agentPediatric COVID-19Respiratory distress syndromeUnderlying medical conditionsPast medical historySignificant clinical benefitIntravenous immunoglobulinElevated markersClinical courseDistress syndromePrompt improvementSevere morbidity